RGD Reference Report - Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease.

Authors: Brito, Victor Gustavo Balera  Patrocinio, Mariana Sousa  de Sousa, Maria Carolina Linjardi  Barreto, Ayná Emanuelli Alves  Frasnelli, Sabrina Cruz Tfaile  Lara, Vanessa Soares  Santos, Carlos Ferreira  Oliveira, Sandra Helena Penha 
Citation: Brito VGB, etal., Front Pharmacol. 2020 Nov 11;11:579926. doi: 10.3389/fphar.2020.579926. eCollection 2020.
RGD ID: 329956421
Pubmed: PMID:33364953   (View Abstract at PubMed)
PMCID: PMC7751694   (View Article at PubMed Central)
DOI: DOI:10.3389/fphar.2020.579926   (Journal Full-text)

Periodontal disease (PD) is a prevalent inflammatory disease with the most severe consequence being the loss of the alveolar bone and teeth. We therefore aimed to evaluate the effects of telmisartan (TELM), an angiotensin II type 1 receptor (Agtr1) antagonist, on the PD-induced alveolar bone loss, in Wistar (W) and Spontaneous Hypertensive Rats (SHRs). PD was induced by ligating the lower first molars with silk, and 10 mg/kg TELM was concomitantly administered for 15 days. The hemimandibles were subjected to microtomography, ELISA was used for detecting tumor necrosis factor (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), CXCL3, and CCL2, while qRT-PCR was used for analyzing expression of components of renin-angiotensin system (RAS) (Agt, Ace, Agt1r, Agt2r, Ace2, and Masr), and bone markers (Runx2, Osx, Catnb, Alp, Col1a1, Opn, Ocn, Bsp, Bmp2, Trap, Rank, Rankl, CtsK, Mmp-2, Mmp-9, and osteoclast-associated receptor (Oscar)). The SHR + PD group showed greater alveolar bone loss than the W + PD group, what was significantly inhibited by treatment with TELM, especially in the SHR group. Additionally, TELM reduced the production of TNF-α, IL-1β, and CXCL3 in the SHR group. The expression of Agt increased in the groups with PD, while Agtr2 reduced, and TELM reduced the expression of Agtr1 and increased the expression of Agtr2, in W and SHRs. PD did not induce major changes in the expression of bone formation markers, except for the expression of Alp, which decreased in the PD groups. The bone resorption markers expression, Mmp9, Ctsk, and Vtn, was higher in the SHR + PD group, compared to the respective control and W + PD group. However, TELM attenuated these changes and increased the expression of Runx2 and Alp. Our study suggested that TELM has a protective effect on the progression of PD, especially in hypertensive animals, as evaluated by the resorption of the lower alveolar bone. This can be partly explained by the modulation in the expression of Angiotensin II receptors (AT1R and AT2R), reduced production of inflammatory mediators, the reduced expression of resorption markers, and the increased expression of the bone formation markers.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
ACE2HumanAlveolar Bone Loss treatmentISOAce2 (Rattus norvegicus)associated with periodontal diseaseRGD 
ACP5HumanAlveolar Bone Loss treatmentISOAcp5 (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
AGTR1HumanAlveolar Bone Loss treatmentISOAgtr1a (Rattus norvegicus)associated with periodontal diseaseRGD 
AGTR2HumanAlveolar Bone Loss treatmentISOAgtr2 (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
ALPLHumanAlveolar Bone Loss treatmentISOAlpl (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
Ace2MouseAlveolar Bone Loss treatmentISOAce2 (Rattus norvegicus)associated with periodontal diseaseRGD 
Ace2RatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
Acp5MouseAlveolar Bone Loss treatmentISOAcp5 (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
Acp5RatAlveolar Bone Loss treatmentIEP associated with hypertension and periodontal diseaseRGD 
Agtr1aMouseAlveolar Bone Loss treatmentISOAgtr1a (Rattus norvegicus)associated with periodontal diseaseRGD 
Agtr1aRatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
Agtr2MouseAlveolar Bone Loss treatmentISOAgtr2 (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
Agtr2RatAlveolar Bone Loss treatmentIEP associated with hypertension and periodontal diseaseRGD 
AlplMouseAlveolar Bone Loss treatmentISOAlpl (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
AlplRatAlveolar Bone Loss treatmentIEP associated with hypertension and periodontal diseaseRGD 
CTSKHumanAlveolar Bone Loss treatmentISOCtsk (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
CXCL1HumanAlveolar Bone Loss treatmentISOCxcl3 (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
CtskMouseAlveolar Bone Loss treatmentISOCtsk (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
CtskRatAlveolar Bone Loss treatmentIEP associated with hypertension and periodontal diseaseRGD 
Cxcl3MouseAlveolar Bone Loss treatmentISOCxcl3 (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
Cxcl3RatAlveolar Bone Loss treatmentIEP associated with hypertension and periodontal diseaseRGD 
IL10HumanAlveolar Bone Loss treatmentISOIl10 (Rattus norvegicus)associated with periodontal diseaseRGD 
IL1BHumanAlveolar Bone Loss treatmentISOIl1b (Rattus norvegicus)associated with periodontal diseaseRGD 
IL6HumanAlveolar Bone Loss treatmentISOIl6 (Rattus norvegicus)associated with periodontal diseaseRGD 
ITGAVHumanAlveolar Bone Loss treatmentISOItgav (Rattus norvegicus)associated with periodontal diseaseRGD 
Il10MouseAlveolar Bone Loss treatmentISOIl10 (Rattus norvegicus)associated with periodontal diseaseRGD 
Il10RatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
Il1bMouseAlveolar Bone Loss treatmentISOIl1b (Rattus norvegicus)associated with periodontal diseaseRGD 
Il1bRatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
Il6RatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
Il6MouseAlveolar Bone Loss treatmentISOIl6 (Rattus norvegicus)associated with periodontal diseaseRGD 
ItgavRatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
ItgavMouseAlveolar Bone Loss treatmentISOItgav (Rattus norvegicus)associated with periodontal diseaseRGD 
MAS1HumanAlveolar Bone Loss treatmentISOMas1 (Rattus norvegicus)associated with periodontal diseaseRGD 
MMP2HumanAlveolar Bone Loss treatmentISOMmp2 (Rattus norvegicus)associated with periodontal diseaseRGD 
MMP9HumanAlveolar Bone Loss treatmentISOMmp9 (Rattus norvegicus)associated with periodontal diseaseRGD 
Mas1RatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
Mas1MouseAlveolar Bone Loss treatmentISOMas1 (Rattus norvegicus)associated with periodontal diseaseRGD 
Mmp2MouseAlveolar Bone Loss treatmentISOMmp2 (Rattus norvegicus)associated with periodontal diseaseRGD 
Mmp2RatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
Mmp9MouseAlveolar Bone Loss treatmentISOMmp9 (Rattus norvegicus)associated with periodontal diseaseRGD 
Mmp9RatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
OSCARHumanAlveolar Bone Loss treatmentISOOscar (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
OscarMouseAlveolar Bone Loss treatmentISOOscar (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
OscarRatAlveolar Bone Loss treatmentIEP associated with hypertension and periodontal diseaseRGD 
PPARGHumanAlveolar Bone Loss treatmentISOPparg (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
PpargRatAlveolar Bone Loss treatmentIEP associated with hypertension and periodontal diseaseRGD 
PpargMouseAlveolar Bone Loss treatmentISOPparg (Rattus norvegicus)associated with hypertension and periodontal diseaseRGD 
TNFHumanAlveolar Bone Loss treatmentISOTnf (Rattus norvegicus)associated with periodontal diseaseRGD 
TNFRSF11AHumanAlveolar Bone Loss treatmentISOTnfrsf11a (Rattus norvegicus)associated with periodontal diseaseRGD 
TNFRSF11BHumanAlveolar Bone Loss treatmentISOTnfrsf11b (Rattus norvegicus)associated with periodontal diseaseRGD 
TNFSF11HumanAlveolar Bone Loss treatmentISOTnfsf11 (Rattus norvegicus)associated with periodontal diseaseRGD 
TnfMouseAlveolar Bone Loss treatmentISOTnf (Rattus norvegicus)associated with periodontal diseaseRGD 
TnfRatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
Tnfrsf11aMouseAlveolar Bone Loss treatmentISOTnfrsf11a (Rattus norvegicus)associated with periodontal diseaseRGD 
Tnfrsf11aRatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
Tnfrsf11bRatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
Tnfrsf11bMouseAlveolar Bone Loss treatmentISOTnfrsf11b (Rattus norvegicus)associated with periodontal diseaseRGD 
Tnfsf11MouseAlveolar Bone Loss treatmentISOTnfsf11 (Rattus norvegicus)associated with periodontal diseaseRGD 
Tnfsf11RatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
VTNHumanAlveolar Bone Loss treatmentISOVtn (Rattus norvegicus)associated with periodontal diseaseRGD 
VtnRatAlveolar Bone Loss treatmentIEP associated with periodontal diseaseRGD 
VtnMouseAlveolar Bone Loss treatmentISOVtn (Rattus norvegicus)associated with periodontal diseaseRGD 
AGTHumanhypertension treatmentISOAgt (Rattus norvegicus) RGD 
AgtRathypertension treatmentIEP  RGD 
AgtMousehypertension treatmentISOAgt (Rattus norvegicus) RGD 
BMP2Humanhypertension treatmentISOBmp2 (Rattus norvegicus) RGD 
Bmp2Rathypertension treatmentIEP  RGD 
Bmp2Mousehypertension treatmentISOBmp2 (Rattus norvegicus) RGD 

Gene-Chemical Interaction Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
ACE2Humantelmisartan decreases expression ISOAce2 (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of rats with periodontal diseaseRGD 
ACP5Humantelmisartan decreases activityISOAcp5 (Rattus norvegicus)telmisartan decreases enzyme activity of Trap and Acp5 in serum of rats with periodontal diseaseRGD 
AGTR1Humantelmisartan decreases expression ISOAgtr1a (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of rats with periodontal diseaseRGD 
AGTR2Humantelmisartan increases expression ISOAgtr2 (Rattus norvegicus)telmisartan increases expression of mRNA in mandible of rats with periodontal diseaseRGD 
ALPLHumantelmisartan increases activityISOAlpl (Rattus norvegicus)telmisartan increases enzyme activity of Alpl in serum of rats with periodontal diseaseRGD 
Ace2Rattelmisartan decreases expression EXP telmisartan decreases expression of mRNA in mandible of rats with periodontal diseaseRGD 
Ace2Mousetelmisartan decreases expression ISOAce2 (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of rats with periodontal diseaseRGD 
Acp5Rattelmisartan decreases activityEXP telmisartan decreases enzyme activity of Trap and Acp5 in serum of rats with periodontal diseaseRGD 
Acp5Mousetelmisartan decreases activityISOAcp5 (Rattus norvegicus)telmisartan decreases enzyme activity of Trap and Acp5 in serum of rats with periodontal diseaseRGD 
Agtr1aRattelmisartan decreases expression EXP telmisartan decreases expression of mRNA in mandible of rats with periodontal diseaseRGD 
Agtr1aMousetelmisartan decreases expression ISOAgtr1a (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of rats with periodontal diseaseRGD 
Agtr2Rattelmisartan increases expression EXP telmisartan increases expression of mRNA in mandible of rats with periodontal diseaseRGD 
Agtr2Mousetelmisartan increases expression ISOAgtr2 (Rattus norvegicus)telmisartan increases expression of mRNA in mandible of rats with periodontal diseaseRGD 
AlplRattelmisartan increases activityEXP telmisartan increases enzyme activity of Alpl in serum of rats with periodontal diseaseRGD 
AlplMousetelmisartan increases activityISOAlpl (Rattus norvegicus)telmisartan increases enzyme activity of Alpl in serum of rats with periodontal diseaseRGD 
CTSKHumantelmisartan decreases expression ISOCtsk (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of rats with periodontal diseaseRGD 
CXCL1Humantelmisartan decreases expression ISOCxcl3 (Rattus norvegicus)telmisartan decreases expression of protein in mandible of SHR rats with periodontal diseaseRGD 
CtskRattelmisartan decreases expression EXP telmisartan decreases expression of mRNA in mandible of rats with periodontal diseaseRGD 
CtskMousetelmisartan decreases expression ISOCtsk (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of rats with periodontal diseaseRGD 
Cxcl3Rattelmisartan decreases expression EXP telmisartan decreases expression of protein in mandible of SHR rats with periodontal diseaseRGD 
Cxcl3Mousetelmisartan decreases expression ISOCxcl3 (Rattus norvegicus)telmisartan decreases expression of protein in mandible of SHR rats with periodontal diseaseRGD 
IBSPHumantelmisartan increases expression ISOIbsp (Rattus norvegicus)telmisartan increases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
IL10Humantelmisartan decreases expression ISOIl10 (Rattus norvegicus)telmisartan decreases expression of protein in mandible of WKY rats with periodontal diseaseRGD 
IL1BHumantelmisartan decreases expression ISOIl1b (Rattus norvegicus)telmisartan decreases expression of protein in mandible of SHR rats with periodontal diseaseRGD 
IbspRattelmisartan increases expression EXP telmisartan increases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
IbspMousetelmisartan increases expression ISOIbsp (Rattus norvegicus)telmisartan increases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
Il10Rattelmisartan decreases expression EXP telmisartan decreases expression of protein in mandible of WKY rats with periodontal diseaseRGD 
Il10Mousetelmisartan decreases expression ISOIl10 (Rattus norvegicus)telmisartan decreases expression of protein in mandible of WKY rats with periodontal diseaseRGD 
Il1bRattelmisartan decreases expression EXP telmisartan decreases expression of protein in mandible of SHR rats with periodontal diseaseRGD 
Il1bMousetelmisartan decreases expression ISOIl1b (Rattus norvegicus)telmisartan decreases expression of protein in mandible of SHR rats with periodontal diseaseRGD 
MMP2Humantelmisartan decreases expression ISOMmp2 (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
MMP9Humantelmisartan decreases expression ISOMmp9 (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal diseaseRGD 
Mmp2Rattelmisartan decreases expression EXP telmisartan decreases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
Mmp2Mousetelmisartan decreases expression ISOMmp2 (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
Mmp9Rattelmisartan decreases expression EXP telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal diseaseRGD 
Mmp9Mousetelmisartan decreases expression ISOMmp9 (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal diseaseRGD 
RUNX2Humantelmisartan increases expression ISORunx2 (Rattus norvegicus)telmisartan increases expression of mRNA in mandible of rats with periodontal diseaseRGD 
Runx2Rattelmisartan increases expression EXP telmisartan increases expression of mRNA in mandible of rats with periodontal diseaseRGD 
Runx2Mousetelmisartan increases expression ISORunx2 (Rattus norvegicus)telmisartan increases expression of mRNA in mandible of rats with periodontal diseaseRGD 
SPP1Humantelmisartan increases expression ISOSpp1 (Rattus norvegicus)telmisartan increases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
Spp1Rattelmisartan increases expression EXP telmisartan increases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
Spp1Mousetelmisartan increases expression ISOSpp1 (Rattus norvegicus)telmisartan increases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
TNFHumantelmisartan decreases expression ISOTnf (Rattus norvegicus)telmisartan decreases expression of protein in mandible of SHR rats with periodontal diseaseRGD 
TNFRSF11BHumantelmisartan increases expression ISOTnfrsf11b (Rattus norvegicus)telmisartan increases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
TNFSF11Humantelmisartan decreases expression ISOTnfsf11 (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal diseaseRGD 
TnfRattelmisartan decreases expression EXP telmisartan decreases expression of protein in mandible of SHR rats with periodontal diseaseRGD 
TnfMousetelmisartan decreases expression ISOTnf (Rattus norvegicus)telmisartan decreases expression of protein in mandible of SHR rats with periodontal diseaseRGD 
Tnfrsf11bMousetelmisartan increases expression ISOTnfrsf11b (Rattus norvegicus)telmisartan increases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
Tnfrsf11bRattelmisartan increases expression EXP telmisartan increases expression of mRNA in mandible of WKY rats with periodontal diseaseRGD 
Tnfsf11Rattelmisartan decreases expression EXP telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal diseaseRGD 
Tnfsf11Mousetelmisartan decreases expression ISOTnfsf11 (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal diseaseRGD 
VTNHumantelmisartan decreases expression ISOVtn (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal diseaseRGD 
VtnRattelmisartan decreases expression EXP telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal diseaseRGD 
VtnMousetelmisartan decreases expression ISOVtn (Rattus norvegicus)telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal diseaseRGD 

Objects Annotated

Genes (Rattus norvegicus)
Ace2  (angiotensin converting enzyme 2)
Acp5  (acid phosphatase 5, tartrate resistant)
Agt  (angiotensinogen)
Agtr1a  (angiotensin II receptor, type 1a)
Agtr2  (angiotensin II receptor, type 2)
Alpl  (alkaline phosphatase, biomineralization associated)
Bmp2  (bone morphogenetic protein 2)
Ctsk  (cathepsin K)
Cxcl3  (C-X-C motif chemokine ligand 3)
Ibsp  (integrin-binding sialoprotein)
Il10  (interleukin 10)
Il1b  (interleukin 1 beta)
Il6  (interleukin 6)
Itgav  (integrin subunit alpha V)
Mas1  (MAS1 proto-oncogene, G protein-coupled receptor)
Mmp2  (matrix metallopeptidase 2)
Mmp9  (matrix metallopeptidase 9)
Oscar  (osteoclast associated Ig-like receptor)
Pparg  (peroxisome proliferator-activated receptor gamma)
Runx2  (RUNX family transcription factor 2)
Spp1  (secreted phosphoprotein 1)
Tnf  (tumor necrosis factor)
Tnfrsf11a  (TNF receptor superfamily member 11A)
Tnfrsf11b  (TNF receptor superfamily member 11B)
Tnfsf11  (TNF superfamily member 11)
Vtn  (vitronectin)

Genes (Mus musculus)
Ace2  (angiotensin converting enzyme 2)
Acp5  (acid phosphatase 5, tartrate resistant)
Agt  (angiotensinogen)
Agtr1a  (angiotensin II receptor, type 1a)
Agtr2  (angiotensin II receptor, type 2)
Alpl  (alkaline phosphatase, liver/bone/kidney)
Bmp2  (bone morphogenetic protein 2)
Ctsk  (cathepsin K)
Cxcl3  (C-X-C motif chemokine ligand 3)
Ibsp  (integrin binding sialoprotein)
Il10  (interleukin 10)
Il1b  (interleukin 1 beta)
Il6  (interleukin 6)
Itgav  (integrin alpha V)
Mas1  (MAS1 oncogene)
Mmp2  (matrix metallopeptidase 2)
Mmp9  (matrix metallopeptidase 9)
Oscar  (osteoclast associated receptor)
Pparg  (peroxisome proliferator activated receptor gamma)
Runx2  (runt related transcription factor 2)
Spp1  (secreted phosphoprotein 1)
Tnf  (tumor necrosis factor)
Tnfrsf11a  (tumor necrosis factor receptor superfamily, member 11a, NFKB activator)
Tnfrsf11b  (tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin))
Tnfsf11  (tumor necrosis factor (ligand) superfamily, member 11)
Vtn  (vitronectin)

Genes (Homo sapiens)
ACE2  (angiotensin converting enzyme 2)
ACP5  (acid phosphatase 5, tartrate resistant)
AGT  (angiotensinogen)
AGTR1  (angiotensin II receptor type 1)
AGTR2  (angiotensin II receptor type 2)
ALPL  (alkaline phosphatase, biomineralization associated)
BMP2  (bone morphogenetic protein 2)
CTSK  (cathepsin K)
CXCL1  (C-X-C motif chemokine ligand 1)
IBSP  (integrin binding sialoprotein)
IL10  (interleukin 10)
IL1B  (interleukin 1 beta)
IL6  (interleukin 6)
ITGAV  (integrin subunit alpha V)
MAS1  (MAS1 proto-oncogene, G protein-coupled receptor)
MMP2  (matrix metallopeptidase 2)
MMP9  (matrix metallopeptidase 9)
OSCAR  (osteoclast associated Ig-like receptor)
PPARG  (peroxisome proliferator activated receptor gamma)
RUNX2  (RUNX family transcription factor 2)
SPP1  (secreted phosphoprotein 1)
TNF  (tumor necrosis factor)
TNFRSF11A  (TNF receptor superfamily member 11a)
TNFRSF11B  (TNF receptor superfamily member 11b)
TNFSF11  (TNF superfamily member 11)
VTN  (vitronectin)


Additional Information